KREMEN2

Across TCGA pan-cancer cohorts, KREMEN2 RNA is linked to patient survival in 27 of 34 cancer types, making it the most broadly survival-associated KREMEN2 data layer compared with 1 for mutation status.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher KREMEN2 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated KREMEN2 expression acts as an unfavorable survival marker, although some lineages such as UVM and STAD show a favorable association.

KIRC, UVM, and LIHC are the cancer types where KREMEN2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	DFS	Median	All	0.540	0.701	<.001	146	view →
UVM	OS	Tertile	II,III,IV	0.961	0.452	<.001	88	view →
LIHC	OS	Quartile	All	0.422	0.740	<.001	66	view →
LUAD	DFS	Median	All	0.269	0.440	<.001	66	view →
BLCA	DFS	Quartile	All	0.264	0.473	.001	62	view →
ACC	DFS	Quartile	II,III,IV	0.253	0.762	.001	55	view →
KIRP	DFS	Median	All	0.787	0.937	<.001	54	view →
STAD	OS	Quartile	III,IV	0.717	0.471	.001	38	view →
BRCA	OS	Quartile	III,IV	0.730	0.903	.003	27	view →
COAD	OS	Tertile	All	0.734	0.914	.005	24	view →
UCEC	DFS	Median	All	0.869	0.923	.008	24	view →
SARC	OS	Quartile	All	0.683	0.843	.012	21	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 27 lineages.

KREMEN2–KIRC (DFS)

Open the KIRC breakdown →